Shire Seeking 'Tuck-in' Rather Than Large-Scale M&A As It Integrates Dyax And Baxalta
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data
Shire, Sanofi and Amgen were among the companies presenting at the Bank of America Merrill Lynch Global Healthcare Conference Sept. 14-16 in London. Here are some key takeaways from those presentations.
Shire's Xiidra Gets Advantageous Label Covering Signs, Symptoms Of Dry Eye Disease
By examining the "totality of the data" including a Phase II study, FDA approved drug for both measures of dry eye, despite mixed results in pivotal trials.